HK1108283A1 - Alkil-pyridines as 11-beta inhibitors for diabetes - Google Patents

Alkil-pyridines as 11-beta inhibitors for diabetes

Info

Publication number
HK1108283A1
HK1108283A1 HK08102253.0A HK08102253A HK1108283A1 HK 1108283 A1 HK1108283 A1 HK 1108283A1 HK 08102253 A HK08102253 A HK 08102253A HK 1108283 A1 HK1108283 A1 HK 1108283A1
Authority
HK
Hong Kong
Prior art keywords
alkil
pyridines
diabetes
beta inhibitors
inhibitors
Prior art date
Application number
HK08102253.0A
Other languages
English (en)
Inventor
Kurt Amrein
Daniel Hunziker
Bernd Kuhn
Alexander Mayweg
Werner Neidhart
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35276680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1108283(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1108283A1 publication Critical patent/HK1108283A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK08102253.0A 2004-10-04 2008-02-28 Alkil-pyridines as 11-beta inhibitors for diabetes HK1108283A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04104856 2004-10-04
PCT/EP2005/010372 WO2006037501A1 (en) 2004-10-04 2005-09-26 Alkil-pyridines as 11-beta inhibitors for diabetes

Publications (1)

Publication Number Publication Date
HK1108283A1 true HK1108283A1 (en) 2008-05-02

Family

ID=35276680

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08102253.0A HK1108283A1 (en) 2004-10-04 2008-02-28 Alkil-pyridines as 11-beta inhibitors for diabetes

Country Status (19)

Country Link
US (1) US7482341B2 (zh)
EP (1) EP1799647A1 (zh)
JP (2) JP5414990B2 (zh)
KR (1) KR100874313B1 (zh)
CN (1) CN101035762B (zh)
AR (1) AR054688A1 (zh)
AU (1) AU2005291561B2 (zh)
BR (1) BRPI0516454A (zh)
CA (1) CA2582276C (zh)
HK (1) HK1108283A1 (zh)
IL (1) IL182310A0 (zh)
MX (1) MX2007003913A (zh)
MY (1) MY139522A (zh)
NO (1) NO20071658L (zh)
NZ (1) NZ554014A (zh)
RU (1) RU2383533C2 (zh)
TW (1) TWI298721B (zh)
WO (1) WO2006037501A1 (zh)
ZA (1) ZA200702716B (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101035762B (zh) * 2004-10-04 2010-09-29 霍夫曼-拉罗奇有限公司 用于糖尿病的作为11-β抑制剂的烷基(alkil)-吡啶类
WO2006106423A2 (en) * 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
RU2007145434A (ru) * 2005-05-10 2009-06-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Бициклические производные в качестве модуляторов ионных каналов
CA2610903A1 (en) * 2005-06-16 2006-12-21 Pfizer Inc. N-(pyridin-2-yl)-sulfonamide derivatives
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
WO2008035306A1 (en) 2006-09-21 2008-03-27 Piramal Life Sciences Limited 3 -amino- pyridine derivatives for the treatment of metabolic disorders
CA2734710A1 (en) * 2007-08-22 2009-02-26 Proteologics Ltd. Pyrimidine and pyridine derivatives as posh and posh-ap inhibitors
PL2324018T3 (pl) * 2008-07-25 2014-02-28 Boehringer Ingelheim Int Cykliczne inhibitory dehydrogenazy 11 beta-hydroksysteroidowej typu 1
US8871208B2 (en) * 2009-12-04 2014-10-28 Abbvie Inc. 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
WO2012027392A2 (en) * 2010-08-24 2012-03-01 Brigham Young University Antimetastatic compounds
EP2687507B1 (en) * 2011-03-14 2016-03-09 Taisho Pharmaceutical Co., Ltd. Nitrogen-containing condensed heterocyclic compound
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
CN104974084A (zh) * 2015-07-19 2015-10-14 佛山市赛维斯医药科技有限公司 一类胺基二吡啶叔醇结构的11β-HSD1抑制剂及其用途
TW201811766A (zh) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
RU2652993C1 (ru) * 2017-06-07 2018-05-04 федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации Новое 2-стирилпроизводное 4-(2,6-диметил-4-оксо-5-фенил-4н-пиримидин-1-ил)-бензсульфамида, обладающее эндотелеопротекторной активностью
WO2022266794A1 (zh) * 2021-06-21 2022-12-29 武汉睿健医药科技有限公司 Oct4高选择性活化剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0001899D0 (sv) * 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
AU2002353717B2 (en) * 2001-11-22 2006-08-03 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MXPA04004837A (es) * 2001-11-22 2004-08-02 Biovitrum Ab Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
TW200503994A (en) * 2003-01-24 2005-02-01 Novartis Ag Organic compounds
PL378295A1 (pl) * 2003-02-24 2006-03-20 Arena Pharmaceuticals, Inc. Podstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu glukozy oraz profilaktyka i leczenie zaburzeń tego metabolizmu
WO2005040135A1 (ja) * 2003-10-24 2005-05-06 Ono Pharmaceutical Co., Ltd. 抗ストレス薬およびその医薬用途
WO2005060963A1 (en) * 2003-12-19 2005-07-07 Pfizer Inc. Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
CN1897944A (zh) * 2003-12-19 2007-01-17 辉瑞有限公司 用于治疗糖尿病和肥胖症的11－β－羟基类固醇脱氢酶－1型(11－β－HSD－1 ) 抑制剂苯磺酰胺基－吡啶－2－基衍生物和相关化合物
CN101035762B (zh) * 2004-10-04 2010-09-29 霍夫曼-拉罗奇有限公司 用于糖尿病的作为11-β抑制剂的烷基(alkil)-吡啶类

Also Published As

Publication number Publication date
CA2582276A1 (en) 2006-04-13
EP1799647A1 (en) 2007-06-27
WO2006037501A9 (en) 2007-08-02
NO20071658L (no) 2007-05-03
JP2008515826A (ja) 2008-05-15
JP5414990B2 (ja) 2014-02-12
KR20070063527A (ko) 2007-06-19
MX2007003913A (es) 2007-05-21
NZ554014A (en) 2010-06-25
JP5351199B2 (ja) 2013-11-27
WO2006037501A1 (en) 2006-04-13
AU2005291561B2 (en) 2010-02-25
AU2005291561A1 (en) 2006-04-13
RU2383533C2 (ru) 2010-03-10
US7482341B2 (en) 2009-01-27
IL182310A0 (en) 2007-07-24
CN101035762A (zh) 2007-09-12
AR054688A1 (es) 2007-07-11
KR100874313B1 (ko) 2008-12-18
JP2011157373A (ja) 2011-08-18
RU2007116431A (ru) 2008-11-10
CA2582276C (en) 2011-09-13
TWI298721B (en) 2008-07-11
US20060074237A1 (en) 2006-04-06
MY139522A (en) 2009-10-30
CN101035762B (zh) 2010-09-29
BRPI0516454A (pt) 2008-09-02
TW200616958A (en) 2006-06-01
ZA200702716B (en) 2008-07-30

Similar Documents

Publication Publication Date Title
HK1108283A1 (en) Alkil-pyridines as 11-beta inhibitors for diabetes
ZA200707650B (en) Azolylacylguanidines as ß-secretase inhibitors
EP1718638A4 (en) NEW COMPOUNDS
GB0400812D0 (en) Novel compounds
GB0405628D0 (en) Novel compounds
GB0402140D0 (en) Novel compounds
GB0402496D0 (en) Novel compounds
ZA200700162B (en) Novel heterocyclic compounds
EP1805132A4 (en) NEW COMPOUNDS
EP1796793A4 (en) NEW CONNECTIONS
GB0402357D0 (en) Novel compounds
GB0427403D0 (en) Novel compounds I
GB0402355D0 (en) Novel compounds
GB0402812D0 (en) Novel compounds
HU0400305D0 (en) Set for spine-fixture
GB0402356D0 (en) Novel compounds
GB0516967D0 (en) Inhibitors
GB0404105D0 (en) Novel compounds
GB0402380D0 (en) Novel compounds
GB0506443D0 (en) Novel inhibitors
GB0408300D0 (en) Novel inhibitors
HU0400020V0 (en) Case for cigarette-packet
GB0400460D0 (en) Novel compounds
GB0406029D0 (en) Novel compounds
GB0402110D0 (en) Novel compounds

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140926